Advertisement

Data From the 2021 San Antonio Breast Cancer Symposium
Posted: 12/11/2021 | By: Liz Janetschek Pasini

Question 1 of 5

The PADA-1 trial discovered that a switch from treatment with an aromatase inhibitor plus palbociclib to fulvestrant to palbociclib may improve progression-free survival among patients with HR-positive breast cancer and what kind of emergent genetic mutation?

Choose 1